Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic Adi Platform, Advancing Toward First-in-Human Clinical Trials
Aditxt的子公司Adimune成功完成其免疫調節治療Adi平台的臨床前療效和安全性研究,向首次人體臨床試驗邁進。
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic Adi Platform, Advancing Toward First-in-Human Clinical Trials
Aditxt的子公司Adimune成功完成其免疫調節治療Adi平台的臨床前療效和安全性研究,向首次人體臨床試驗邁進。
使用瀏覽器的分享功能,分享給你的好友吧